Policy & Regulation
Altruist Biologics' Hangzhou ADC facility approved for segmented production
9 July 2026 - Contract development and manufacturing organisation (CDMO) Altruist Biologics, a subsidiary of Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801), announced on Wednesd...
Northwest Biotherapeutics presents updated DCVax-L Phase III trial survival data for glioblastoma
9 July 2026 - Northwest Biotherapeutics (OTCQB:NWBO)(NWBio), a biotechnology company developing DCVax personalised immune therapies for solid tumour cancers, announced on Wednesday that the company�...
Lynk Pharmaceuticals reports first patient dosed in Phase II clinical trial for vitiligo treatment
9 July 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug development company focused on immune and inflammatory diseases, announced on Wednesday that the first patient has been succ...
HanchorBio plans combination research with late-stage cancer drug resistance specialist InxMed
9 July 2026 - Taiwan-listed clinical-stage biotech HanchorBio Inc (TWSE:7827) announced on Wednesday that it is looking to broaden the development path for HCB101, its lead oncology asset, through a n...
Keenova reports positive Phase 3 results for XIAFLEX in plantar fibromatosis
8 July 2026 - US-based therapeutics company Keenova Therapeutics plc on Wednesday reported positive Phase 3 results for XIAFLEX, its collagenase treatment for plantar fibromatosis, a chronic condition...
GE HealthCare and Mayo Clinic launch prostate cancer theranostics research study
8 July 2026 - Healthcare solutions provider GE HealthCare Technologies Inc (NASDAQ: GEHC) and non-profit organisation Mayo Clinic announced on Wednesday the launch of the MI-BET (Molecular Imaging Bio...